NIH Consens Statement. 1994;12(1):1-23.
The National Institutes of Health Consensus Development Conference on Helicobacter pylori in Peptic Ulcer Disease brought together specialists in gastroenterology, surgery, infectious diseases, epidemiology, and pathology, as well as the public, to address the following questions: (1) What is the causal relationship of H. pylori to upper gastrointestinal disease? (2) How does one diagnose and eradicate H. pylori infection? (3) Does eradication of H. pylori infection benefit the patient with peptic ulcer disease? (4) What is the relationship between H. pylori infection and gastric malignancy? (5) Which H. pylori-infected patients should be treated? (6) What are the most important questions that must be addressed by future research in H. pylori infections? Following 1 1/2 days of presentations by experts and discussion by the audience, a consensus panel weighed the evidence and prepared their consensus statement. Among their findings, the consensus panel concluded that: (1) ulcer patients with H. pylori infection require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation with the illness or on recurrence; (2) the value of treating non-ulcer dyspepsia patients with H. pylori infection remains to be determined; and (3) the interesting relationship between H. pylori infection and gastric cancers requires further exploration. The full text of the consensus panel's statement follows.
美国国立卫生研究院关于幽门螺杆菌与消化性溃疡疾病的共识发展会议汇聚了胃肠病学、外科、传染病学、流行病学和病理学领域的专家以及公众，以探讨以下问题：（1）幽门螺杆菌与上消化道疾病的因果关系是什么？（2）如何诊断和根除幽门螺杆菌感染？（3）根除幽门螺杆菌感染对消化性溃疡疾病患者是否有益？（4）幽门螺杆菌感染与胃癌之间的关系是什么？（5）哪些幽门螺杆菌感染患者应该接受治疗？（6）幽门螺杆菌感染未来研究必须解决的最重要问题是什么？在专家进行了1.5天的报告以及听众进行讨论之后，一个共识小组权衡了证据并准备了他们的共识声明。在他们的研究结果中，共识小组得出结论：（1）幽门螺杆菌感染的溃疡患者无论初次发病还是复发，除了使用抗分泌药物外，还需要使用抗菌药物进行治疗；（2）治疗幽门螺杆菌感染的非溃疡性消化不良患者的价值仍有待确定；（3）幽门螺杆菌感染与胃癌之间有趣的关系需要进一步探索。共识小组声明的全文如下。
